UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Following the approval of toripalimab, the drug is expected to get a first-mover advantage in the first-line treatment setting within the PD-1 market in RCC for China, says data and analytics company GlobalData. 11 August 2023
USA-based American Gene Technologies International (AGT) and 10X Capital Venture Acquisition Corp III (10X III; (NYSE: VCXB), a special purpose acquisition company (SPAC), have entered into a merger agreement for a business combination that would result in the combined company being a publicly listed company following the business combination to be renamed Addimmune, which is expected to trade under the ticker symbol “HIV”. 11 August 2023
Building on lessons learned during the coronavirus pandemic, the UK government is to open a major new vaccine research center aimed at combating future threats. 10 August 2023
Danish drugmaker Novo Nordisk has reported sales in line with expectations at 108 billion Danish krone ($15.98 billion) for the first six months in 2023, up 30% from the same period a year earlier. 10 August 2023
San Diego, USAbased cancer specialist Mirati Therapeutics is to replace its chief executive, David Meek, with former CEO Charles Baum taking over on an interim basis. 10 August 2023
Anglo-Swedish pharma major AstraZeneca’s research into mRNA vaccines is to be aided by the use of Chinese biotech firm CanSino Biologics' manufacturing platform. 10 August 2023
The US Food and Drug Administration (FDA) yesterday issued a Complete Response Letter (CRL) regarding US drug developer Galera Therapeutics New Drug Application (NDA) for avasopasem manganese for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. 10 August 2023
US hearing loss treatment specialist Decibel Therapeutics (Nasdaq: DBTX) saw its share rocket 77% to $4.95 pre-market on Wednesday, on the news that it has agreed to be acquired by US biotech major Regeneron Pharmaceuticals. 10 August 2023
First granted US accelerated approval in 2020, the Food and Drug Administration on Wednesday converted this to regular approval of Gavreto (pralsetinib) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 10 August 2023
Positive data for a new kind of medicine, a BTK inhibitor developed by Novartis, could pave the way to improved treatment options for people with chronic spontaneous urticaria. 9 August 2023
San Diego, USA-based next generation RNA therapeutics company ADARx Pharmaceuticals today revealed it has closed an oversubscribed Series C financing of $200 million. 9 August 2023
Emergent BioSolutions has announced that it is reducing investment in and de-emphasizing focus on growth in its contract development and manufacturing organization (CDMO) services business. 9 August 2023
The prevalence of non-alcoholic steatohepatitis (NASH), a more advanced stage of nonalcoholic fatty liver disease (NAFLD), continues to increase. 9 August 2023
Japanese drug major Astellas Pharma has announced a strategic investment to support the advancement of Poseida Therapeutics’ commitment to redefining cancer cell therapy. The news pushed Poseida’s shares up as much as 24% to $2.69. 9 August 2023
South Korean vaccine developer SK bioscience’s shares were up 4.6% at 84,500 won, after it announced its decision to make an equity investment of around $85 million in US biotech Novavax. 9 August 2023
Sino-American biotech Terns Pharmaceuticals yesterday revealed positive top-line results from the Phase IIa DUET clinical trial of TERN-501, both alone and in combination with TERN-101, for the treatment of non-alcoholic steatohepatitis (NASH). 9 August 2023
Germany’s Bayer might have a new chief executive in Bill Anderson, but many of the challenges faced by his predecessor Werner Baumann remain. 8 August 2023
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023